Skip to Content

UK Edition. Click here for US version.

FRESENIUS PROPOFOL 1% EMULSION FOR INJECTION OR INFUSION

Active substance(s): PROPOFOL

View full screen / Print PDF » Download PDF ⇩
Transcript
PACKAGE LEAFLET: INFORMATION FOR THE USER
Propofol 1% (10 mg/1 ml) Fresenius emulsion for injection or infusion
Propofol
Read all of this leaflet carefully before you are given this medicine because it contains important
information for you.
- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor, pharmacist or nurse.
- If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side
effects not listed in this leaflet. See section 4.

What is in this leaflet:
1.
2.
3.
4.
5.
6.

What Propofol Fresenius is and what it is used for
What you need to know before you are given Propofol Fresenius
How to use Propofol Fresenius
Possible side effects
How to store Propofol Fresenius
Contents of the pack and other information

1. What Propofol Fresenius is and what it is used for
Propofol Fresenius belongs to a group of medicines called ‘general anaesthetics’. General anaesthetics are
used to cause unconsciousness (sleep) so that surgical operations or other procedures can be performed.
They can also be used to sedate you (so that you are sleepy but not completely asleep).
Propofol 1 % (10 mg/1 ml) Fresenius is used to:
• induce and maintain general anaesthesia in adults and children > 1 month.
• sedate patients > 16 years of age receiving artificial respiration in intensive care.
• sedate adults and children > 1 month during diagnostic and surgical procedures, alone or in
combination with local or regional anaesthesia.
2. What you need to know before you are given Propofol Fresenius
Do not use Propofol Fresenius
-

if you are allergic to propofol or any of the other ingredients of this medicine (listed in section 6).
if you are allergic to soya or peanut (see “Propofol Fresenius contains soya-bean oil and sodium” at
the end of section 2).
in patients of 16 years of age or younger for sedation in intensive care.

Warnings and precautions
Talk to your doctor, pharmacist or nurse before you are given Propofol Fresenius and if any of the
subsequent mentioned applies to you or applied to you in the past.
You should not receive Propofol Fresenius, or only under extreme caution and intensive monitoring, if
you:
- have advanced heart failure
UK-IE Propofol 1% PILV002

Page 1 of 10

-

have any other serious disease of the heart
are receiving electroconvulsive therapy (ECT, a treatment for psychiatric problems)

In general, Propofol Fresenius should be given with caution to elderly or weak patients.
Before receiving Propofol Fresenius, tell your anaesthetist or intensive care doctor if you have:
- heart disease
- lung disease
- kidney disease
- liver disease
- seizures (epilepsy)
- a raised pressure inside the skull (raised intracranial pressure). In combination with low blood
pressure the amount of blood reaching the brain may be decreased.
- altered levels of fat in the blood. If you receiving total parenteral nutrition (feeding through a vein),
the levels of fat in your blood must be monitored.
if your body has lost lots of water (you are hypovolaemic).
If you have any of the following conditions, they must be treated before you receive Propofol Fresenius:
- heart failure
- when there is insufficient blood reaching the tissues (circulatory failure)
- severe breathing problems (respiratory failure)
- dehydration (hypovolaemia)
- seizures (epilepsy)
Propofol Fresenius may increase the risk of
- epileptic seizures
- a nervous reflex that slows the heart rate (vagotonia, bradycardia)
- changes in the blood flow to the organs of the body (haemodynamic effects on the cardiovascular
system) if you are overweight and receive high doses of Propofol Fresenius.
Involuntary movements can occur during sedation with Propofol Fresenius. The doctors will take into
account how this might affect surgical procedures being performed under sedation and will take the
necessary precautions.
Very occasionally, after anaesthesia, there may be a period of unconsciousness associated with stiffness of
the muscles. This requires observation by the medical staff but no other treatment. It will resolve
spontaneously.
The injection of Propofol Fresenius can be painful. A local anaesthetic can be used to reduce this pain but
can have its own side effects.
You will not be allowed to leave the hospital until you are fully awake.
If you are able to go home shortly after receiving propofol you should not go home unaccompanied.
Children and adolescents
The use of Propofol 1 % (10 mg/1 ml) Fresenius is not recommended in new-born infants or children
younger than 1 month.
Propofol 1 % (10 mg/1 ml) Fresenius must not be given to children and adolescents younger than 16 years
of age for sedation in the intensive care unit, since its safety has not been demonstrated in this patient
group for this indication.
Other medicines and Propofol Fresenius
UK-IE Propofol 1% PILV002

Page 2 of 10

Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
You must take special care if you are also taking/receiving any of the following medicines:
- Premedications (your anaesthetist will know which medicines can be influenced by Propofol
Fresenius)
- Other anaesthetics, including general, regional, local and inhalational anaesthetics (Lower doses of
Propofol Fresenius may be required. Your anaesthetist will know this.)
- Painkillers (analgesics)
- Strong painkillers (fentanyl or opioids)
- Parasympatholytic agents (medicines used to treat e.g. painful cramps of organs, asthma or
Parkinson's disease)
- Benzodiazepines (medicines used to treat anxiety)
- Suxamethonium (muscle relaxant)
- Drugs that affect many of the internal body functions such as the heart rate, e.g. atropine
- Alcohol containing medicines or beverages
- Neostigmine (medicine used to treat a disease called myasthenia gravis)
- Cyclosporine (medicine used to prevent transplant rejections)
Propofol Fresenius with food and drink
After you have been given Propofol Fresenius, you should not eat, drink or consume alcohol until fully
recovered.
Pregnancy, breast-feeding and fertility
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your
doctor or pharmacist for advice before taking this medicine.
Propofol Fresenius should not be given to pregnant women unless necessary.
You should stop breast-feeding and discard any breast milk for 24 hours after receiving Propofol
Fresenius.
Driving and using machines
After having Propofol you may still feel sleepy for some time. Do not drive or use any tools or machines
until you are sure the effects have worn off.
If you are able to go home shortly after receiving Propofol, do not drive a car or go home unaccompanied.
Ask your doctor when you can start doing these activities again and when you can go back to work.
Propofol Fresenius contains soya-bean oil and sodium
Propofol Fresenius contains soya-bean oil. This can rarely cause severe allergic reactions (see “Do not use
Propofol Fresenius”). Tell your doctor if you know that you have allergic reactions to soya-bean oil or
peanut.
This medicinal product contains less than 1 mmol (23 mg) sodium per 100 ml, i.e. essentially ´sodiumfree`.

3. How to use Propofol Fresenius
Propofol Fresenius will only be given to you in hospitals or suitable therapy units by or under the direct
supervision of your anaesthetist or intensive care doctor.
Dosage

UK-IE Propofol 1% PILV002

Page 3 of 10

The dose you are given will vary depending on your age, body weight and physical condition. The doctor
will give the correct dose to start and to sustain anaesthesia or to achieve the required level of sedation by
carefully watching your responses and vital signs (pulse, blood pressure, breathing, etc).
You may need several different medicines to keep you asleep or sleepy, free from pain, breathing in a
healthy way and to keep your blood pressure steady. The doctor will decide which medicines you need
and when you need them.
Adults
Most people need 1.5 - 2.5 mg propofol per kg body weight to make them go to sleep (induction of
anaesthesia), and then 4 to 12 mg propofol per kg body weight per hour after this to keep them asleep
(maintenance of anaesthesia). For sedation, doses of 0.3 to 4.0 mg propofol per kg body weight per hour
are usually sufficient.
For sedation during surgical and diagnostic procedures in adults, most patients will require 0.5 - 1 mg
propofol per kg body weight over 1 to 5 minutes for onset of sedation. Maintenance of sedation may be
accomplished by titrating Propofol Fresenius infusion to the desired level of sedation. Most patients will
require 1.5 - 4.5 mg propofol per kg body weight per hour. The infusion may be supplemented by bolus
administration of 10 - 20 mg propofol (1 – 2 ml Propofol 1 % (10 mg/1 ml) Fresenius) if a rapid increase
of the depth of sedation is required.
To provide sedation for ventilated patients older than 16 years of age under intensive care conditions the
dose will be adjusted according to the depth of sedation required. Usually satisfactory sedation is achieved
by continuous infusion with administration rates in the range of 0.3 to 4.0 mg propofol per kg body weight
per hour. Rates of infusion greater than 4.0 mg propofol per kg bodyweight per hour are not
recommended.
Use in children and adolescents over one month of age
The use of Propofol Fresenius is not recommended in children younger than 1 month.
Special care should also be observed when administering Propofol 1 % (10 mg/1 ml) Fresenius to children
less than 3 years of age. However, evidence now available does not suggest that this is any less safe than
in children older than 3 years.
The dose should be adjusted according to age and/or body weight. Most patients over 8 years of age
require approximately 2.5 mg/kg bodyweight Propofol Fresenius to make them go to sleep (induction of
anaesthesia). In younger children, especially between the age of 1 month and 3 years, dose requirements
may be higher (2.5 - 4 mg/kg bodyweight).
Rates in the region of 9 - 15 mg/kg/h usually achieve satisfactory anaesthesia to keep them asleep
(maintenance of anaesthesia). In younger children, especially between the age of 1 month and 3 years,
dose requirements may be higher.
For sedation during surgical and diagnostic procedures in children over 1 month of age with Propofol 1 %
(10 mg/1 ml) Fresenius most paediatric patients require 1 - 2 mg/kg bodyweight propofol for onset of
sedation. Maintenance of sedation may be accomplished by titrating Propofol Fresenius infusion to the
desired level of sedation. Most patients require 1.5 - 9 mg/kg/h propofol. The infusion may be
supplemented by bolus administration of up to 1 mg/kg bodyweight if a rapid increase of depth of sedation
is required.
Propofol 1 % (10 mg/1 ml) Fresenius must not be given to children and adolescents younger than 16 years
of age for sedation in the intensive care unit, since its safety has not been demonstrated in this patient
group for this indication.
Method of administration
UK-IE Propofol 1% PILV002

Page 4 of 10

Propofol Fresenius is for intravenous use, usually on the back of your hand or in the forearm. Your
anaesthetist may use a needle or cannula (a fine plastic tube). Propofol Fresenius will be injected into a
vein either manually or by electric pumps. An electric pump may be used to give the injection for long
operations and for use in intensive care.
Elderly and weak patients
Elderly and weak patients may require lower doses.
Duration of treatment
When used for sedation, Propofol Fresenius must not be administered for more than 7 days.
If you received more Propofol than you should
Your doctor will ensure that you receive the right amount of Propofol for you and for the procedure you
are undergoing.
However, different people need different doses and if you do receive too much for you, your anaesthetist
may need to take measures to make sure your heart and breathing are adequately supported. This is why
anaesthetic drugs are only administered by doctors trained in anaesthesia or in the care of patients in
intensive care.
If you have any further questions on the use of this medicine, ask your anaesthetist or intensive care
doctor.

4. Possible side effects
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Side effects that can happen during anaesthesia
The following side effects can happen during anaesthesia (while the injection is being given to you or
when you are sleepy or asleep). Your doctor will be looking out for these. If they happen, your doctor will
give you appropriate treatment.
Very common (may affect more than 1 in 10 people)
• A feeling of pain at the site of the injection (while the injection is being given, before you fall asleep).
Common (may affect up to 1 in 10 people)
• Slow or fast heartbeat
• Low blood pressure
• Changes in your breathing pattern (low respiratory rate, breathing arrest)
• Hiccups
• Cough (may also happen when you wake up)
Uncommon (may affect up to 1 in 100 people)

Swelling and redness or blood clots at the vein along the injection site.
Rare (may affect up to 1 in 1,000 people)
• Twitching and shaking of your body, or fits (may also happen when you wake up).
Very rare (may affect up to 1 in 10, 000 people)
• Serious allergic reaction which causes difficulty in breathing, swollen and reddened skin, hot flushes

UK-IE Propofol 1% PILV002

Page 5 of 10




Build up of fluid in the lungs which can make you very breathless (may also happen when you wake
up)
Unusual colour of urine (may also happen when you wake up).

Not known (frequency cannot be estimated from the available data)
• Involuntary movements
• Severe skin and tissue reaction following accidental application beside the vein.
Side effects that can happen after anaesthesia
The following side effects can happen after anaesthesia (when you are waking up or after you have woken
up).
Common (may affect up to 1 in 10 people)
• Headache
• Feeling sick (nausea), being sick (vomiting).
• Cough.
Rare (may affect up to 1 in 1,000 people)
• Dizziness, chills and sensations of cold
• Excitations
Very rare (may affect up to 1 in 10,000 people)
• Being unconscious after the operation (when this has happened, the patients have recovered without
problems)
• Inflamed pancreas (pancreatitis) which causes severe stomach pain (a causal relationship could not be
shown)
• Fever following surgery
Not known (frequency cannot be estimated from the available data)
• Feeling euphoric
• Feeling sexually aroused
• Irregular heart beat
• Changes in ECG (Brugada type ECG)
• Increase in liver size
• Kidney failure
• Breakdown of muscle cells (rhabdomyolysis), increase in acidity of your blood, high potassium and
fat levels in your blood, heart failure
• Drug abuse, mostly by healthcare professionals
When Propofol Fresenius is administered in combination with lidocaine (a local anaesthetic used to reduce
the pain at the site of injection), certain side effects may occur rarely:
- dizziness
- vomiting
- sleepiness
- fits
- a slowing of the heart rate (bradycardia)
- irregular heartbeat (cardiac arrhythmias)
- shock
Reporting of side effects
UK-IE Propofol 1% PILV002

Page 6 of 10

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects
not listed in this leaflet. You can also report side effects directly via the national reporting system below
By reporting side effects you can help provide more information on the safety of this medicine.
For the UK:
You can report side effects directly via the Yellow Card Scheme at:
http://www.mhra.gov.uk/yellowcard
For Ireland:
You can also report side effects directly via
HPRA Pharmacovigilance,
Earlsfort Terrace,
IRL - Dublin 2;
Tel: +353 1 6764971;
Fax: +353 1 6762517.
Website: http://www.hpra.ie
E-mail: medsafety@hpra.ie
5. How to store Propofol Fresenius
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the ampoule/vial and the outer packaging
after EXP. The expiry date refers to the last day of that month.
Do not store above 25 °C.
Do not freeze.
After opening the product must be used immediately.
Administration systems with undiluted Propofol Fresenius should be replaced 12 hours after opening of
the ampoule or vial. Dilutions with 5 % w/v glucose or 0.9 % w/v sodium chloride intravenous infusion
solution or an admixture with 1 % preservative-free lidocaine injection solution (at least 2 mg propofol per
ml) should be prepared aseptically (controlled and validated conditions preserved) immediately before
administration and has to be administered within 6 hours after preparation.
Containers should be shaken before use.
Do not use this medicine if you notice two layers after shaking the emulsion.
Use only homogeneous preparations and undamaged containers.
For single use. Any unused emulsion must be discarded.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw
away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information
What Propofol 1 % (10 mg/1 ml) Fresenius contains
-

The active substance is propofol.

UK-IE Propofol 1% PILV002

Page 7 of 10

1 ml emulsion contains 10 mg propofol.
Each 20 ml ampoule contains 200 mg propofol.
Each 50 ml vial contains 500 mg propofol.
Each 100 ml vial contains 1000 mg propofol.
-

The other ingredients are refined soya-bean oil, purified egg phosphatides, glycerol, oleic acid,
sodium hydroxide, water for injections.

What Propofol Fresenius looks like and contents of the pack
Propofol Fresenius is a white oil-in-water emulsion for injection or infusion.
Propofol Fresenius is available in colourless glass ampoules or glass vials. The glass vials are sealed with
rubber stoppers.
Pack sizes:
Packs containing 5 glass ampoules with 20 ml emulsion
Packs containing 1 glass vial with 50 or 100 ml emulsion
Packs containing 10 glass vials with 50 or 100 ml emulsion
Packs containing 15 glass vials with 50 or 100 ml emulsion
Not all pack sizes may be marketed.
Marketing Authorisation Holder and Manufacturer
Marketing Authorisation Holder:
Fresenius Kabi Limited
Cestrian Court
Eastgate Way
Manor Park
Runcorn
Cheshire
WA7 1NT
United Kingdom
Manufacturer:
Fresenius Kabi Austria GmbH
Hafnerstraße 36
A-8055 Graz
Austria
Fresenius Kabi AB
Rapsgatan 7
S-75174 Uppsala
Sweden

This medicinal product is authorised in the Member States of the EEA under the following names:
Name of the member
state
UK-IE Propofol 1% PILV002

Name of the medicinal product
Page 8 of 10

Belgium
Germany
Greece
France
Ireland
Portugal
Spain
Sweden
United Kingdom

Propofol Fresenius 1 %
Propofol 1% (10mg/1 ml) Fresenius, Emulsion zur Injektion oder
Infusion
Propofol 1 % Fresenius
Propofol Fresenius 10 mg/ml, emulsion injectable ou pour perfusion
Fresenius Propofol 1 %
Propofol 1 % Fresenius
Propofol Fresenius 10 mg/ml emulsión para inyección o perfusión
Propofol Fresenius Kabi 10 mg/ml
Fresenius Propofol 1 %

This leaflet was last revised in July 2015.

--------------------------------------------------------------------------------------------------------------------------The following information is intended for healthcare professionals only:
Propofol 1 % (10 mg/1 ml) Fresenius should not be mixed prior to administration with injection or
infusion solutions other than 5 % w/v glucose or 0.9 % w/v sodium chloride intravenous infusion solution
or 1% preservative free lidocaine injection solution. Final propofol concentration must not be below
2 mg/ml.
For single use. Any unused emulsion must be discarded.
Containers should be shaken before use.
If two layers can be seen after shaking the emulsion should not be used.
Use only homogeneous preparations and undamaged containers.
Prior to use, the ampoule neck or rubber membrane should be cleaned using an alcohol spray or a swab
dipped in alcohol. After use, tapped containers must be discarded.
Propofol should be given by those trained in anaesthesia (or, where appropriate, doctors trained in the care
of patients in Intensive Care).
Patients should be constantly monitored and facilities for maintenance of a patent airway, artificial
ventilation, oxygen enrichment and other resuscitative facilities should be readily available at all times.
Propofol should not be administered by the person conducting the diagnostic or surgical procedure.
Abuse of, and dependence on propofol, predominantly by health care professionals, have been reported.
As with other general anaesthetics, the administration of propofol without airway care may result in fatal
respiratory complications.
When propofol is administered for conscious sedation, for surgical and diagnostic procedures, patients
should be continually monitored for early signs of hypotension, airway obstruction and oxygen
desaturation.
Propofol 1 % (10 mg/1 ml) Fresenius may be administered undiluted or diluted in 5 % w/v glucose or
0.9 % w/v sodium chloride intravenous infusion solutions.
5 % w/v Glucose intravenous infusion solution, 0.9 % w/v sodium chloride intravenous infusion solution
or 0.18 % w/v sodium chloride and 4 % w/v glucose intravenous infusion solution may be given through
the same infusion set. Propofol 1 % (10 mg/1 ml) Fresenius must not be mixed with any other solutions
for infusion or injection. Co-administration of other medicinal products or fluids added to the Propofol
UK-IE Propofol 1% PILV002

Page 9 of 10

Fresenius infusion line must occur close to the cannula site using a Y-piece connector or a three-way
valve.
Propofol Fresenius is a lipid containing emulsion without antimicrobial preservatives and may support
rapid growth of microorganisms.
The emulsion must be drawn aseptically into a sterile syringe or giving set immediately after opening the
ampoule or breaking the vial seal. Administration must commence without delay.
Asepsis must be maintained for both Propofol Fresenius and the infusion equipment throughout the
infusion period. Propofol Fresenius must not be administered through a microbiological filter.
Infusion of undiluted Propofol 1 % (10 mg/1 ml) Fresenius:
The use of a burette, drop counter, syringe pump or volumetric infusion pump to control the infusion rate
is recommended when Propofol Fresenius is infused undiluted.
As usual for fat emulsions, the infusion of Propofol Fresenius via one infusion system must not exceed 12
hours. The infusion set for Propofol Fresenius must be changed at least every 12 hours.
Infusion of diluted Propofol 1 % (10 mg/1 ml) Fresenius:
Burettes, drop counters or volumetric infusion pumps should always be used to control infusion rates. The
maximum dilution must not exceed 1 part of Propofol 1 % (10 mg/1 ml) Fresenius with 4 parts of 5 % w/v
glucose or 0.9 % w/v sodium chloride intravenous infusion solution (minimum concentration 2 mg
propofol per ml). The mixture should be prepared aseptically immediately prior to administration and
must be administered within 6 hours after preparation.
Lidocaine may be added to the solution (20 parts of Propofol 1 % (10 mg/1 ml) Fresenius with up to 1 part
of 1 % preservative free lidocaine solution for injection) to reduce pain at the site of injection of Propofol
1 % (10 mg/1 ml) Fresenius. Lidocaine must not be used in patients with hereditary acute porphyria.
Muscle relaxants like atracurium and mivacurium should only be administered after flush of the same
infusion site used for Propofol Fresenius.

UK-IE Propofol 1% PILV002

Page 10 of 10

Expand view ⇕

Source: Medicines and Healthcare Products Regulatory Agency

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide